BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38071053)

  • 1. [Levels and Clinical Significances of sPD-1 and sPD-L1 in Peripheral Blood of Lymphoma Patients].
    Liu XL; He P; Lei J; Zou LX; Peng L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1733-1738. PubMed ID: 38071053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.
    Zhang X; Liu L; Zhou S; Zhao K; Song Z; Hu G; Zhang T; Li Y; Qiu L; Li L; Qian Z; Meng B; Pan Y; Ren X; Wang X; Zhang H; Fu K
    Hematol Oncol; 2019 Aug; 37(3):270-276. PubMed ID: 31074879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of PD-1/PD-L1 in peripheral blood and tumor tissues of patients with classical Hodgkin's lymphoma.
    Feng X; Luo X; Yang Y; Fan Y; Ye Q
    Medicine (Baltimore); 2023 Nov; 102(44):e35757. PubMed ID: 37933048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
    Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
    Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between PD-1 and sPD-L1 expression levels in peripheral blood of DLBCL patients and their clinicopathological characteristics.
    Wang L; Cao C; Qiu J; Zhang J; He Q; Song L; Xie L; Ma J
    Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):44-50. PubMed ID: 38430041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis.
    Shen H; Ji Y; Zhou D; Zhang Y; Wang W; Sun J; Zhang W
    Hematology; 2019 Dec; 24(1):392-398. PubMed ID: 30890046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Levels of programmed death-1 and programmed death ligand-1 in the peripheral blood of patients with oral squamous cell carcinoma and its clinical implications].
    Zhang P; Ouyang S; Wang J; Huang Z; Wang J; Liao L
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2015 Oct; 33(5):529-33. PubMed ID: 26688950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of soluble programmed death-1, soluble programmed death ligand 1 proteins and immune status in patients with oral lichen planus].
    Luo L; Shu M; Li S; Cai Y
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2015 Oct; 50(10):585-9. PubMed ID: 26757624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Soluble programmed death-1 and soluble programmed death ligand 1 protein expression and immune status in patients with recurrent aphthous ulcer].
    Nan J; Liang L; Li L; Xiaoqin S; Xing J; Yang C
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2017 Jun; 35(3):286-290. PubMed ID: 28675014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in lymphoma: a systematic review and meta-analysis.
    Ding Y; Sun C; Hu L; Xiong S; Zhai Z
    Ann Hematol; 2023 Sep; 102(9):2425-2434. PubMed ID: 37382610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma.
    Guo X; Wang J; Jin J; Chen H; Zhen Z; Jiang W; Lin T; Huang H; Xia Z; Sun X
    Transl Oncol; 2018 Jun; 11(3):779-785. PubMed ID: 29698935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
    Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M
    Front Immunol; 2020; 11():580335. PubMed ID: 33224142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
    Wang H; Wang L; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Li ZM; Lu Y
    Oncotarget; 2016 May; 7(22):33035-45. PubMed ID: 27105512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
    Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
    Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
    Cho I; Lee H; Yoon SE; Ryu KJ; Ko YH; Kim WS; Kim SJ
    BMC Cancer; 2020 Feb; 20(1):120. PubMed ID: 32054467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unbalanced expression of membrane-bound and soluble inducible costimulator and programmed cell death 1 in patients with myasthenia gravis.
    Yan X; Gu Y; Wang C; Sun S; Wang X; Tian J; Wang M; Ji X; Duan X; Gao H; Fang Q; Dong W; Zhang X; Xue Q
    Clin Immunol; 2019 Oct; 207():68-78. PubMed ID: 31374257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
    Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
    [No Abstract]   [Full Text] [Related]  

  • 18. The significance of PD-1/PD-L1 imbalance in ulcerative colitis.
    Shi W; Zhang Y; Hao C; Guo X; Yang Q; Du J; Hou Y; Cao G; Li J; Wang H; Fang W
    PeerJ; 2023; 11():e15481. PubMed ID: 37273534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients.
    El-Ghammaz AMS; Gadallah HA; Kamal G; Maher MM; Mohamad MA
    Clin Exp Med; 2018 Nov; 18(4):505-512. PubMed ID: 29876769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma levels of soluble programmed death ligand 1 (sPD-L1) in WHO II/III nasopharyngeal carcinoma (NPC): A preliminary study.
    Yang J; Hu M; Bai X; Ding X; Xie L; Ma J; Fan B; Yu J
    Medicine (Baltimore); 2019 Sep; 98(39):e17231. PubMed ID: 31574833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.